Horses for Courses: Why VCs Stick with Private, Not Public Investing
This article was originally published in Start Up
Executive Summary
With public markets up but private equity markets still in the doldrums, why don't VCs shift their strategies to favor purchasing public biotechs? They have--a bit. But public investing doesn't exploit a VC's competitive advantages or justify the relatively high management fees they charge.